Kaposi Sarcoma Relapse Reported Despite HIV Viral Suppression

Relapse Cases Challenge Existing Beliefs

Doctors have reported cases of Kaposi Sarcoma (KS) relapsing in HIV-positive patients who had achieved complete viral suppression. This development contradicts the long-held assumption that controlling HIV replication alone is enough to prevent KS recurrence.

The findings, presented recently at a medical conference, indicate that the cancer can return even when blood tests show no detectable HIV. This suggests that the virus may leave a lasting impact on the immune system that antiretroviral therapy cannot fully reverse.

Understanding Kaposi Sarcoma in the HIV Context

Kaposi Sarcoma is a cancer that causes lesions to grow in the skin, lymph nodes, and internal organs. It is caused by the Kaposi Sarcoma-associated herpesvirus (KSHV). In people with HIV, a weakened immune system allows KSHV to trigger tumour growth.

For years, standard treatment has focused on antiretroviral therapy (ART) to suppress HIV. Once the viral load becomes undetectable, the immune system often recovers enough to keep KS in check. These new relapse cases show that this recovery may be incomplete for some patients.

Study Details and Observations

Researchers tracked a cohort of HIV patients who had been successfully treated for KS and had undetectable HIV viral loads for at least six months. Despite this, a subset experienced new KS lesions or growth of existing ones.

The relapses were not linked to drug resistance or treatment interruptions. Instead, the team observed that certain immune cells, particularly CD4+ T-cells, remained dysfunctional even when their counts were normal. This immune dysfunction may allow KSHV to reactivate and cause cancer.

Implications for Clinical Practice

These findings have immediate implications for how doctors monitor HIV patients with a history of KS. Regular skin and mucosal checks should continue even after viral suppression is achieved. Patients reporting new lumps, discolouration, or swelling need prompt evaluation.

Treatment protocols may need to be updated. Some patients might benefit from longer courses of chemotherapy or targeted therapies that address immune dysfunction directly. Doctors are now debating whether routine immune function tests should be added to standard follow-up for high-risk patients.

What Remains Unknown

The exact mechanism behind these relapses is still unclear. Researchers are investigating whether certain strains of KSHV are more aggressive or if specific genetic markers in patients predict a higher risk of recurrence.

Larger studies are needed to determine the true frequency of this phenomenon. Current data come from a small number of cases, and experts warn against drawing broad conclusions prematurely.

Patients and clinicians alike should remain vigilant. The message from this study is clear: undetectable HIV does not always mean immune health is fully restored.

Ongoing research will focus on identifying biomarkers that can flag patients at risk of KS relapse before lesions appear. Until then, close monitoring remains the best defence.